Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new Add-On seizure drug stay safe for kids over time?

NCT ID NCT04715646

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial is testing the long-term safety of brivaracetam, an anti-seizure medication, when used alongside other epilepsy treatments in children. Researchers are monitoring for side effects, including serious ones, over an extended period. The study includes children who previously took part in related trials, as well as new participants in Japan. The goal is to see if brivaracetam remains safe and tolerable for young patients with epilepsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
brivaracetam (an anti-seizure medication taken by mouth as tablets or oral solution)
What this could lead to
If successful, this could confirm that brivaracetam is safe for long-term use in children with epilepsy, offering a well-tolerated add-on option to control seizures.
What could go wrong
This is an open-label, single-arm study with no placebo group, so results may be less reliable. Side effects like dizziness, drowsiness, or more serious events are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY

Contacts and locations

Locations

  • Ep0156 204

    WITHDRAWN

    Leuven, Belgium

  • Ep0156 207

    WITHDRAWN

    Loos, France

  • Ep0156 209

    WITHDRAWN

    Freiburg im Breisgau, Germany

  • Ep0156 210

    COMPLETED

    Budapest, Hungary

  • Ep0156 223

    COMPLETED

    Aguascalientes, Mexico

  • Ep0156 230

    COMPLETED

    Roma, Italy

  • Ep0156 232

    COMPLETED

    Miskolc, Hungary

  • Ep0156 237

    COMPLETED

    Durham, North Carolina, 27710, United States

  • Ep0156 240

    WITHDRAWN

    Prague, Czechia

  • Ep0156 247

    COMPLETED

    Budapest, Hungary

  • Ep0156 248

    COMPLETED

    Seville, Spain

  • Ep0156 259

    COMPLETED

    Hawthorne, New York, 10532, United States

  • Ep0156 401

    COMPLETED

    Poznan, Poland

  • Ep0156 402

    COMPLETED

    Krakow, Poland

  • Ep0156 406

    COMPLETED

    Kielce, Poland

  • Ep0156 603

    COMPLETED

    Guadalajara, Mexico

  • Ep0156 609

    COMPLETED

    Culiacán, Mexico

  • Ep0156 800

    ACTIVE_NOT_RECRUITING

    Gifu, Japan

  • Ep0156 802

    COMPLETED

    Yonago, Japan

  • Ep0156 803

    ACTIVE_NOT_RECRUITING

    Bunkyō City, Japan

  • Ep0156 804

    ACTIVE_NOT_RECRUITING

    Tokyo, Japan

  • Ep0156 805

    ACTIVE_NOT_RECRUITING

    Sapporo, Japan

  • Ep0156 806

    ACTIVE_NOT_RECRUITING

    Kyoto, Japan

  • Ep0156 807

    ACTIVE_NOT_RECRUITING

    Hiroshima, Japan

  • Ep0156 808

    ACTIVE_NOT_RECRUITING

    Chūō, Japan

  • Ep0156 809

    ACTIVE_NOT_RECRUITING

    Shimotsuke, Japan

  • Ep0156 810

    ACTIVE_NOT_RECRUITING

    Yokohama, Japan

  • Ep0156 811

    ACTIVE_NOT_RECRUITING

    Nagoya, Japan

  • Ep0156 812

    ACTIVE_NOT_RECRUITING

    Niigata, Japan

  • Ep0156 813

    ACTIVE_NOT_RECRUITING

    Kōshi, Japan

  • Ep0156 814

    RECRUITING

    Shizuoka, Japan

  • Ep0156 815

    RECRUITING

    Kodaira-shi, Japan

  • Ep0156 816

    RECRUITING

    Sendai, Japan

  • Ep0156 817

    RECRUITING

    Osaka, Japan

  • Ep0156 818

    RECRUITING

    Ōbu, Japan

  • Ep0156 819

    RECRUITING

    Ōmura, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.